Visser C J, Meijers M, van Garderen-Hoetmer A, Klijn J G, Foekens J A, Woutersen R A
Department of Pathology, TNO Nutrition and Food Research Institute, Zeist, The Netherlands.
Int J Cancer. 1995 Nov 27;63(5):732-7. doi: 10.1002/ijc.2910630521.
The present 12-month study was carried out to investigate the effects of the aromatase inhibitor aminoglutethimide, alone and in combination with orchiectomy, on pancreatic carcinogenesis in azaserine-treated rats and N-nitrosobis(2-oxopropyl)-amine-treated hamsters. Treatment of the animals started 4 months after the last injection with the carcinogen. They were surgically castrated and/or treated with aminoglutethimide. Aminoglutethimide-treated rats developed less pancreatic tumours than did untreated controls. Multiplicity of (pre-)-neoplastic acinar lesions was lower in orchiectomized rats than in intact rats. Inhibition of pancreatic carcinogenesis was most pronounced in rats that were both orchiectomized and treated with aminoglutethimide. These effects were statistically significant after 8 months, but not after 4 months, of treatment. In hamsters, aminoglutethimide showed an enhancing rather than an inhibitory effect on the formation of ductular pancreatic tumours. Castration appeared to have no effect on the development of N-nitrosobis(2-oxopropyl)amine-induced ductular lesions in the pancreas, either alone, or in combination with aminoglutethimide. The present findings indicate that aminoglutethimide, alone and in combination with surgical castration, might be of value for the treatment of pancreatic acinar tumours, whereas the usefulness of aminoglutethimide for treatment of ductular adenocarcinomas of the pancreas is somewhat doubtful.
本为期12个月的研究旨在调查芳香化酶抑制剂氨鲁米特单独使用以及与睾丸切除术联合使用时，对用氮杂丝氨酸处理的大鼠和用N-亚硝基双（2-氧代丙基）胺处理的仓鼠胰腺致癌作用的影响。动物在最后一次注射致癌物4个月后开始接受治疗。它们接受了手术去势和/或氨鲁米特治疗。接受氨鲁米特治疗的大鼠发生的胰腺肿瘤比未治疗的对照组少。去势大鼠的（癌前）腺泡病变的数量比完整大鼠少。在既接受去势又接受氨鲁米特治疗的大鼠中，胰腺致癌作用的抑制最为明显。这些作用在治疗8个月后具有统计学意义，但在治疗4个月后没有统计学意义。在仓鼠中，氨鲁米特对胰腺导管肿瘤的形成显示出促进作用而非抑制作用。单独或与氨鲁米特联合使用时，去势似乎对N-亚硝基双（2-氧代丙基）胺诱导胰腺导管病变的发展没有影响。目前的研究结果表明，氨鲁米特单独使用以及与手术去势联合使用，可能对胰腺腺泡肿瘤的治疗有价值，而氨鲁米特对胰腺导管腺癌治疗的有效性则有些可疑。
